文章摘要

EZH2对弥漫大B细胞淋巴瘤RCHOP方案治疗效果的预测价值

作者: 1刘拥征, 1王伟, 1李岭, 1蒋丽琴, 1谢先顺
1 南华大学附属第二医院肿瘤/血液内科,湖南 衡阳 421000
通讯: 王伟 Email: 490989948@qq.com
DOI: 10.3978/j.issn.2095-6959.2021.03.017

摘要

目的: 探讨Zeste基因增强子(enhancer of zeste homolog 2,EZH2)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)RCHOP方案治疗的效果的预测价值。方法:纳入2017年1月至2018年5月南华大学附属第二医院80例接受RCHOP方案治疗的DLBCL患者,分析患者EZH2表达情况与治疗效果的关系,绘制EZH2预测治疗效果的ROC曲线,并对患者pCR与病理特征的关系进行讨论。结果:80例患者中EZH2高表达者49例,EZH2低表达者31例,DLBCL患者RCHOP治疗的pCR率为51.25%,其中EZH2高表达患者完全缓解(complete response,CR)、客观缓解率(objective response rate,ORR)均明显低于EZH2低表达患者(P<0.05);EZH2预测治疗效果的曲线下面积为0.874(P<0.05);pCR与性别、年龄、美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)得分、淋巴瘤国际预后指数(International Prognostic Index,IPI)得分、乳酸脱氢酶(lactate dehydrogenase,LDH)因素无相关关系(P>0.05);与Hans分型、EZH2表达水平存在一定的相关性(P<0.05)。结论:DLBCL患者EZH2低表达是RCHOP治疗后高pCR率的预测因子,在临床上有助于为DLBCL患者临床治疗提供更好的指导。
关键词: EZH2;弥漫大B细胞淋巴瘤;RCHOP方案;预测价值

Predictive value of EZH2 in the treatment of diffuse large B-cell lymphoma with RCHOP regimen

Authors: 1LIU Yongzheng, 1WANG Wei, 1LI Ling, 1JIANG Liqin, 1XIE Xianshun
1 Tumor Hematology Department, Second Hospital University of South China, Hengyang Hunan 421000, China

CorrespondingAuthor: WANG Wei Email: 490989948@qq.com

Abstract

Objective: To discuss the predictive value of enhancer of zeste homolog 2 (EZH2) in the treatment of diffuse large B-cell lymphoma (DLBCL) with RCHOP regimen. Methods: A total of 80 patients with DLBCL treated with RCHOP regimen in our hospital from January 2017 to May 2018 were selected. The relationship between EZH2 expression and therapeutic effect was analyzed. The ROC curve of EZH2 predicting therapeutic effect was made. The relationship between pCR and pathological characteristics was discussed. Results: Among 80 patients, 49 had high expression of EZH2, 31 had low expression of EZH2, and 51.25% had pCR in DLBCL patients treated with RCHOP. The complete response (CR) and objective response rate (ORR) in patients with high expression of EZH2 were significantly lower than those in patients with low expression of EZH2 (P<0.05). The predictive effect of EZH2 was 0.874 (P<0.05). There was no correlation between pCR and sex, age, Eastern Cooperative Oncology Group (ECOG) score, International Prognostic Index (IPI) score, lactate dehydrogenase (LDH) factor (P>0.05), but there was correlation between pCR and Hans typing and EZH2 expression level (P<0.05). Conclusion: The low expression of EZH2 in DLBCL patients is a predictor of high pCR rate after RCHOP treatment. It is helpful to provide better guidance for clinical treatment of DLBCL patients.
Keywords: EZH2; diffuse large B-cell lymphoma; RCHOP regimen; predictive value